Molecular Diagnostics, Inc. Announces New Trading Symbol “MCDG”
Added: (Thu Sep 27 2001)
Pressbox (Press Release) -
Chicago, Illinois - 27 September, 2001 : Molecular Diagnostics, Inc (Formerly Ampersand Medical Corporation; OTCBB AMPM) announced today that as of the opening of the markets on Thursday September 27, 2001 the new trading symbol for the Company’s common stock on the Over-The-Counter Bulletin Board market will change from “AMPM to “MCDG”.
The new symbol reflects the change in the name of the Company on September 24, 2001 from Ampersand Medical Corporation to Molecular Diagnostics, Inc. The Company believes that the new name more clearly reflects the business being carried on by the Company.
All market makers in the Company’s common stock will have trading and price information available to them under the new symbol on Thursday, as will the OTCBB and Nasdaq informational websites. Certain Internet sites, which provide stock price quotation information, may process the symbol change into their systems over the next few days.
About Molecular Diagnostics
Molecular Diagnostics, (formerly Ampersand Medical Corporation) develops cost-effective cancer screening systems which can be utilized at the point of care or in a laboratory, to assist in the early detection of cervical, gastrointestinal and other cancers. The InPathä System is being developed to provide medical practitioners with a highly accurate, low-cost, point-of-care cervical cancer screening system. Other products include SAMBA™ Telemedicine software used for medical image processing, database and multimedia case management, telepathology and teleradiology.
Certain statements throughout this release are forward-looking. These statements are based on the Company’s current expectations and involve many risks and uncertainties, such as the possibility that clinical trials will not substantiate the Company’s expectations with respect to the InPathTM System, and other factors set forth in reports and documents filed by Molecular Diagnostics, Inc. with the Securities and Exchange Commission. Molecular Diagnostics, Inc. undertakes no obligation to publicly update or revise any forward-looking statements contained herein.
For more information, contact:
Molecular Diagnostics Inc
414 N. Orleans, Suite 510